健脾生血片治疗急性缺血性脑卒中合并缺铁性贫血患者的临床观察(1)
摘要 目的：研究健脾生血片治療急性缺血性卒中合并缺铁性贫血患者的临床疗效。方法：选取2017年3月至2018年5月福建省泉州市第一医院收治的急性缺血性卒中合并缺铁性贫血患者192例作为研究对象，随机分为观察组和对照组，每组96例。观察组给予健脾生血片治疗，3片/次，3次/d，疗程3个月;对照组给予生血宝合剂治疗，15 mL/次，3次/d，疗程3个月。比较2组患者相关指标。随访发病后6个月残疾率情况和发病后1年缺血性脑卒中复发率及全因死亡率。结果：治疗后3个月，观察组贫血有效率显著高于对照组(P<0.05);观察组血清IL-1β、TNF-α、CRP和hepcidin水平显著下降(P<0.05)，对照组治疗后未显著下降，观察组炎性反应递质水平显著低于对照组(P<0.05);观察组RET、RBC、HGB水平均显著上升(P<0.05)，对照组治疗后未显著上升，观察组血常规指标显著高于对照组(P<0.05);观察组血清铁(SI)、转铁蛋白饱和度(TS)显著升高且与对照组比较差异有统计学意义(P<0.05);2组不良反应比较差异无统计学意义(P>0.05);随访发病后6个月的残疾率，观察组显著低于对照组(P<0.05);随访发病后1年的缺血性卒中复发率，观察组显著低于对照组(P<0.05)，随访后1年2组全因死亡率比较差异无统计学意义(P>0.05)。结论：健脾生血片可有效治疗急性缺血性卒中合并缺铁性贫血且安全有效，值得临床用于缺血性脑卒中及贫血的治疗。
关键词 健脾生血片;急性缺血性卒中;缺铁性贫血
Abstract Objective：To study the clinical efficacy of Jianpi Shengxue Tablets in the treatment of patients with acute ischemic stroke and iron deficiency anemia.Methods：A total of of 192 patients with acute ischemic stroke and iron deficiency anemia admitted to Quanzhou First Hospital，Fujian between March 2017 and May 2018 were selected as the research objects and were randomly divided into an observation group and a control group，with 96 cases in each group.The observation group was given Jianpi Shengxue Tablets treatment，3 tablets/time，3 times/d，for 3 months; the control group was given Shengxuebao mixture treatment，15 mL/time，3 times/d，for 3 months.The related indexes of the 2 groups was compared.The rate of disability after 6 months of onset and the recurrence rate of ischemic stroke 1 year after onset and all-cause mortality were followed up.Results：At 3 months after treatment，the anemia of the observation group was significantly higher than that of the control group(P<0.05).The levels of serum IL-1β，TNF-α，CRP and hepcidin were significantly decreased in the observation group(P<0.05).The control group did not decrease significantly after treatment，and the inflammatory response transmitter level in observation group was significantly lower than the control group(P<0.05); the RET，RBC，and HGB levels in the observation group increased significantly(P<0.05)，and the control group did not significantly increase after treatment.The blood routine index of the observation group was significantly higher than that of the control group(P<0.05); the serum iron(SI)and transferrin saturation(TS)of the observation group were significantly increased and there was significant difference with the control group(P<0.05); the difference in adverse reactions between the 2 groups was not statistically significant(P>0.05); the disability rate of the observation group was significantly lower than that of the control group 6 months after the onset of follow-up(P<0.05); the observation group was significantly lower than the control group(P<0.05).The recurrence rate of ischemic stroke 1 year after the onset of follow-up was significantly lower in the observation group than in the control group(P<0.05).There was no significant difference in all-cause mortality between the 2 groups at 1 year after the follow-up(P>0.05).Conclusion：Jianpi Shengxue Tablets can effectively treat acute ischemic stroke with iron deficiency anemia and is safe and effective.It is worthy of clinical use in the treatment of ischemic stroke and anemia., http://www.100md.com(杨晓霞 李国前 王杰华)
关键词 健脾生血片;急性缺血性卒中;缺铁性贫血
Abstract Objective：To study the clinical efficacy of Jianpi Shengxue Tablets in the treatment of patients with acute ischemic stroke and iron deficiency anemia.Methods：A total of of 192 patients with acute ischemic stroke and iron deficiency anemia admitted to Quanzhou First Hospital，Fujian between March 2017 and May 2018 were selected as the research objects and were randomly divided into an observation group and a control group，with 96 cases in each group.The observation group was given Jianpi Shengxue Tablets treatment，3 tablets/time，3 times/d，for 3 months; the control group was given Shengxuebao mixture treatment，15 mL/time，3 times/d，for 3 months.The related indexes of the 2 groups was compared.The rate of disability after 6 months of onset and the recurrence rate of ischemic stroke 1 year after onset and all-cause mortality were followed up.Results：At 3 months after treatment，the anemia of the observation group was significantly higher than that of the control group(P<0.05).The levels of serum IL-1β，TNF-α，CRP and hepcidin were significantly decreased in the observation group(P<0.05).The control group did not decrease significantly after treatment，and the inflammatory response transmitter level in observation group was significantly lower than the control group(P<0.05); the RET，RBC，and HGB levels in the observation group increased significantly(P<0.05)，and the control group did not significantly increase after treatment.The blood routine index of the observation group was significantly higher than that of the control group(P<0.05); the serum iron(SI)and transferrin saturation(TS)of the observation group were significantly increased and there was significant difference with the control group(P<0.05); the difference in adverse reactions between the 2 groups was not statistically significant(P>0.05); the disability rate of the observation group was significantly lower than that of the control group 6 months after the onset of follow-up(P<0.05); the observation group was significantly lower than the control group(P<0.05).The recurrence rate of ischemic stroke 1 year after the onset of follow-up was significantly lower in the observation group than in the control group(P<0.05).There was no significant difference in all-cause mortality between the 2 groups at 1 year after the follow-up(P>0.05).Conclusion：Jianpi Shengxue Tablets can effectively treat acute ischemic stroke with iron deficiency anemia and is safe and effective.It is worthy of clinical use in the treatment of ischemic stroke and anemia., http://www.100md.com(杨晓霞 李国前 王杰华)